SG11202012015YA - Compositions and methods for the modulation of adaptive immunity - Google Patents

Compositions and methods for the modulation of adaptive immunity

Info

Publication number
SG11202012015YA
SG11202012015YA SG11202012015YA SG11202012015YA SG11202012015YA SG 11202012015Y A SG11202012015Y A SG 11202012015YA SG 11202012015Y A SG11202012015Y A SG 11202012015YA SG 11202012015Y A SG11202012015Y A SG 11202012015YA SG 11202012015Y A SG11202012015Y A SG 11202012015YA
Authority
SG
Singapore
Prior art keywords
sequence
rna
seq
disclosure
composition
Prior art date
Application number
SG11202012015YA
Other languages
English (en)
Inventor
David A Nelles
Ranjan Batra
Eugene Yeo
Original Assignee
Locanabio Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Locanabio Inc filed Critical Locanabio Inc
Publication of SG11202012015YA publication Critical patent/SG11202012015YA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/102—Mutagenizing nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1136—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against growth factors, growth regulators, cytokines, lymphokines or hormones
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/90—Stable introduction of foreign DNA into chromosome
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/20—Type of nucleic acid involving clustered regularly interspaced short palindromic repeats [CRISPR]

Landscapes

  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Endocrinology (AREA)
  • Mycology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
SG11202012015YA 2018-06-08 2019-06-07 Compositions and methods for the modulation of adaptive immunity SG11202012015YA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862682276P 2018-06-08 2018-06-08
PCT/US2019/036050 WO2019236998A1 (en) 2018-06-08 2019-06-07 Compositions and methods for the modulation of adaptive immunity

Publications (1)

Publication Number Publication Date
SG11202012015YA true SG11202012015YA (en) 2021-01-28

Family

ID=68769461

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202012015YA SG11202012015YA (en) 2018-06-08 2019-06-07 Compositions and methods for the modulation of adaptive immunity

Country Status (9)

Country Link
US (2) US20190382759A1 (cg-RX-API-DMAC7.html)
EP (1) EP3801641A4 (cg-RX-API-DMAC7.html)
JP (1) JP2021526860A (cg-RX-API-DMAC7.html)
KR (1) KR20210060429A (cg-RX-API-DMAC7.html)
CN (1) CN113286619A (cg-RX-API-DMAC7.html)
AU (1) AU2019281006A1 (cg-RX-API-DMAC7.html)
CA (1) CA3102783A1 (cg-RX-API-DMAC7.html)
SG (1) SG11202012015YA (cg-RX-API-DMAC7.html)
WO (1) WO2019236998A1 (cg-RX-API-DMAC7.html)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011160052A2 (en) 2010-06-18 2011-12-22 The University Of North Carolina At Chapel Hill Methods and compositions for sequence specific rna endonucleases
EP3765094A4 (en) 2018-03-15 2021-12-22 KSQ Therapeutics, Inc. GENE REGULATORY COMPOSITIONS AND PROCEDURES FOR IMPROVED IMMUNOTHERAPY
CN112930395A (zh) 2018-06-08 2021-06-08 洛卡纳生物股份有限公司 靶向rna的融合蛋白组合物和使用方法
CN113544267B (zh) 2019-01-14 2025-04-18 罗切斯特大学 使用CRISPR-Cas进行靶向核RNA裂解和聚腺苷酸化
EP3999117A4 (en) * 2019-07-12 2023-07-26 Duke University NANOPARTICLE SYSTEMS FOR TARGETED CRISPR/CAS13 DELIVERY AND METHODS OF USE THEREOF
IL303269A (en) 2020-12-03 2023-07-01 Century Therapeutics Inc Genetically engineered cells and uses thereof
US11661459B2 (en) 2020-12-03 2023-05-30 Century Therapeutics, Inc. Artificial cell death polypeptide for chimeric antigen receptor and uses thereof
CN113136376B (zh) * 2021-05-26 2022-10-21 武汉大学 一种Cas12a变体及其在基因编辑中的应用
WO2023150131A1 (en) * 2022-02-01 2023-08-10 The Regents Of The University Of California Method of regulating alternative polyadenylation in rna
CN114848808B (zh) * 2022-03-24 2023-04-25 四川大学 基于阳离子脂多肽及细胞因子的免疫增强剂及制法、应用
CN114720699A (zh) * 2022-04-22 2022-07-08 浙江大学 一种结直肠癌早期预警血清指标及其检测方法和应用
CN116949011A (zh) * 2022-04-26 2023-10-27 中国科学院动物研究所 经分离的Cas13蛋白、基于它的基因编辑系统及其用途
CN115068632A (zh) * 2022-06-22 2022-09-20 华中科技大学同济医学院附属同济医院 Ago2在制备治疗心衰的药物方面的用途及其蛋白、基因、转化体、药物与制备方法
WO2024264035A2 (en) * 2023-06-22 2024-12-26 The General Hospital Corporation Compositions and methods of generating endogenous tdr molecules

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2016359629B2 (en) * 2015-11-23 2023-03-09 Ranjan BATRA Tracking and manipulating cellular RNA via nuclear delivery of CRISPR/Cas9
WO2017093969A1 (en) * 2015-12-04 2017-06-08 Novartis Ag Compositions and methods for immunooncology
US12180499B2 (en) * 2016-10-31 2024-12-31 University Of Florida Research Foundation, Inc. Compositions and methods for impeding transcription of expanded microsatellite repeats
CN110959039B (zh) * 2017-03-15 2025-03-14 博德研究所 新型cas13b直向同源物crispr酶和系统
US10392616B2 (en) * 2017-06-30 2019-08-27 Arbor Biotechnologies, Inc. CRISPR RNA targeting enzymes and systems and uses thereof

Also Published As

Publication number Publication date
WO2019236998A1 (en) 2019-12-12
CA3102783A1 (en) 2019-12-12
EP3801641A4 (en) 2022-09-28
EP3801641A1 (en) 2021-04-14
AU2019281006A1 (en) 2021-01-28
US20240344060A1 (en) 2024-10-17
US20190382759A1 (en) 2019-12-19
JP2021526860A (ja) 2021-10-11
KR20210060429A (ko) 2021-05-26
CN113286619A (zh) 2021-08-20

Similar Documents

Publication Publication Date Title
IL280134A (en) Anti-CD112R preparations and methods
IL277079A (en) Cartirin preparations and methods of use
IL268970A (en) New preparations and methods
SG10202001869VA (en) Cd19 compositions and methods for immunotherapy
SG11202101777VA (en) Methods and compositions for the modification of plants
SG11202103033WA (en) Compositions and methods for the treatment of presbyopia
GB202201860D0 (en) Novel methods and compositions
GB2578519B (en) Compositions and methods and uses relating thereto
WO2015120138A3 (en) AGENTS THAT MODULATE RGMb-NEOGENIN-BMP SIGNALING AND METHODS OF USE THEREOF
SG11202104448WA (en) Compositions and methods
ZA202101362B (en) Compositions and methods for treating the eye
IL266562A (en) Methods and methods for adaptive immune regulation
ZA202101342B (en) Compositions and methods for treating the eye
GB201817444D0 (en) Methods and compositions
GB201815402D0 (en) Compositions and methods and uses relating thereto
ZA202101360B (en) Compositions and methods for treating the eye
IL273699A (en) Sulfazine salt preparations and methods of using them
GB201819987D0 (en) Methods and compositions
ZA202101361B (en) Compositions and methods for treating the eye
IL264977B1 (en) Methods and preparations for treating melanoma
SG11202012283XA (en) Additive composition and method of preparing the same
GB201804092D0 (en) Methods and compositions
HK40049655A (en) Compositions and methods for the modulation of adaptive immunity
PL4013697T3 (pl) Zamknięcie
IL281835A (en) Antimalarial methods and compounds